Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer (Oncogenesis, (2016), 5, 5, (e226), 10.1038/oncsis.2016.32);Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer

Oncogenesis

Volumn 5, Issue 5, 2016, Pages e226-

  Henry, C E ^a   Llamosas, E ^a   Djordjevic, A ^a   Hacker, N F ^a   Ford, C E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013408155     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/s41389-022-00408-4     Document Type: Erratum

References (39)

1. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014; 106.
2. Schildkraut JM, Iversen ES, Akushevich L, Whitaker R, Bentley RC, Berchuck A et al. Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 2013; 22: 1709–1721. DOI: 10.1158/1055-9965.EPI-13-0192
3. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013; 123: 517–525.
4. Helm CW, States JC. Enhancing the efficacy of cisplatin in ovarian cancer treatment—could arsenic have a role. J Ovarian Res 2009; 2: 2. DOI: 10.1186/1757-2215-2-2
5. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364–378. DOI: 10.1016/j.ejphar.2014.07.025
6. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615. DOI: 10.1038/nature10166
7. Leong HS, Galletta L, Etemadmoghadam D, George J, Australian Ovarian Cancer S, Kobel M et al. Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol 2015; 236: 272–277. DOI: 10.1002/path.4536
8. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015; 521: 489–494. DOI: 10.1038/nature14410
9. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198–5208. DOI: 10.1158/1078-0432.CCR-08-0196
10. Ford CE, Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J et al. The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Gynecol Oncol 2014; 134: 338–345. DOI: 10.1016/j.ygyno.2014.06.004
11. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012; 12: 91. DOI: 10.1186/1471-2407-12-91
12. Kurrey NK, Amit K, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005; 97: 155–165. DOI: 10.1016/j.ygyno.2004.12.043
13. Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP et al. Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 2015; 34: 1899–1907. DOI: 10.1038/onc.2014.136
14. Baldwin LA, Hoff JT, Lefringhouse J, Zhang M, Jia C, Liu Z et al. CD151-alpha3beta1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget 2014; 5: 12203–12217. DOI: 10.18632/oncotarget.2622
15. Cui B, Zhang S, Chen L, Yu J, Widhopf GF, Fecteau JF et al. Targeting ROR1 inhibits epithelial–mesenchymal transition and metastasis. Cancer Res 2013; 73: 3649–3660. DOI: 10.1158/0008-5472.CAN-12-3832
16. Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007; 282: 17259–17271. DOI: 10.1074/jbc.M700075200
17. Ford CE, Jary E, Ma S, Nixdorf S, Heinzelmann-Schwarz V, Ward RL. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells. PLoS ONE 2013; 8: e54362. DOI: 10.1371/journal.pone.0054362
18. Kanzawa M, Semba S, Hara S, Itoh T, Yokozaki H. WNT5A is a key regulator of the epithelial–mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells. Pathobiology 2013; 80: 235–244. DOI: 10.1159/000346843
19. Ren D, Minami Y, Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial–mesenchymal transition. Genes Cells 2011; 16: 304–315. DOI: 10.1111/j.1365-2443.2011.01487.x
20. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M. Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci 2003; 94: 593–597. DOI: 10.1111/j.1349-7006.2003.tb01488.x
21. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11–26. DOI: 10.1038/nrc3419
22. Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer 2013; 13: 174. DOI: 10.1186/1471-2407-13-174
23. O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 2010; 29: 34–44. DOI: 10.1038/onc.2009.305
24. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A et al. Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discov 2013; 3: 1378–1393. DOI: 10.1158/2159-8290.CD-13-0005
25. Sun B, Ye X, Lin L, Shen M, Jiang T. Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer. Int J Clin Exp Pathol 2015; 8: 856–861.
26. Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D et al. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both beta-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol 2015; 141: 243–254. DOI: 10.1007/s00432-014-1824-y
27. Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M et al. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget 2015; 6: 40310–40326. DOI: 10.18632/oncotarget.5643
28. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 2015; 15: 668–679. DOI: 10.1038/nrc4019
29. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF II et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA 2014; 111: 17266–17271. DOI: 10.1073/pnas.1419599111
30. Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep 2014; 4: 5811. DOI: 10.1038/srep05811
31. Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol 2015; 309: C444–C456. DOI: 10.1152/ajpcell.00188.2015
32. Barghout SH, Zepeda N, Xu Z, Steed H, Lee CH, Fu Y. Elevated beta-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells. Biochem Biophys Res Commun 2015; 468: 173–178. DOI: 10.1016/j.bbrc.2015.10.138
33. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006; 17 (Suppl 5): v181–v187. DOI: 10.1093/annonc/mdj978
34. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007; 31: 277–283.
35. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY et al. Snail and Slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27: 2059–2068. DOI: 10.1002/stem.154
36. Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun 2016; 7: 10060. DOI: 10.1038/ncomms10060
37. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012; 21: 348–361. DOI: 10.1016/j.ccr.2012.02.008
38. Martinez S, Scerbo P, Giordano M, Daulat AM, Lhoumeau AC, Thome V et al. The PTK7 and ROR2 receptors interact in the vertebrate WNT/PCP pathway. J Biol Chem 2015; 290: 30562–30572. DOI: 10.1074/jbc.M115.697615
39. Geback T, Schulz MM, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. BioTechniques 2009; 46: 265–274. DOI: 10.2144/000113083